Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to $521000.0.

  • Insight Molecular Diagnostics' Share-based Compensation rose 1577.78% to $521000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 1490.22%. This contributed to the annual value of $1.8 million for FY2024, which is 3648.55% down from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Share-based Compensation is $521000.0, which was up 1577.78% from $504000.0 recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Share-based Compensation ranged from a high of $3.2 million in Q3 2022 and a low of $386000.0 during Q2 2024
  • Its 5-year average for Share-based Compensation is $1.2 million, with a median of $834000.0 in 2023.
  • Per our database at Business Quant, Insight Molecular Diagnostics' Share-based Compensation surged by 7309.64% in 2021 and then tumbled by 8151.97% in 2023.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Share-based Compensation stood at $1.7 million in 2021, then soared by 53.61% to $2.6 million in 2022, then plummeted by 81.52% to $484000.0 in 2023, then rose by 3.1% to $499000.0 in 2024, then rose by 4.41% to $521000.0 in 2025.
  • Its last three reported values are $521000.0 in Q3 2025, $504000.0 for Q2 2025, and $473000.0 during Q1 2025.